- Home
- LEXX
LEXX
Lexaria Bioscience Corp.
as 04-23-2025 4:00pm EST
| Founded: | 2004 | Country: | Canada |
| Employees: | N/A | City: | KELOWNA |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 55.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $4.44 | Next Earning Date: | 04-14-2025 |
| Revenue: | $525,923 | Revenue Growth: | 29.95% |
| Revenue Growth (this year): | 30.72% | Revenue Growth (next year): | 31.85% |
Latest Lexaria Bioscience Corp. News
LEXX Breaking Stock News: Dive into LEXX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
a day ago
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Simply Wall St.
19 days ago
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully
ACCESS Newswire
21 days ago
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
ACCESS Newswire
22 days ago
Lexaria's Human GLP-1 Study #5 Begins Dosing
ACCESS Newswire
a month ago
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
ACCESS Newswire
2 months ago
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
ACCESS Newswire
2 months ago
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
ACCESS Newswire
2 months ago
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Compare LEXX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LEXX Lexaria Bioscience Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.